91Â鶹ÌìÃÀÖ±²¥

There may be up to a tenfold difference in risk for infants who are currently treated identically under clinical guidelines. The analysis is an important step toward more personalized pregnancy...

In a recent interview with Dr. Ignacio Garrido-Laguna from the 91Â鶹ÌìÃÀÖ±²¥, we gained fascinating insights into the management of RAS mutations.

An investigational pan-RAS inhibitor—daraxonrasib (RMC-6236)—shows early activity and has a manageable safety profile in patients with previously treated RAS-mutant PDAC, according to data presented at the 2025 ASCO Gastrointestinal Cancers...

The pandemic may be related to a spike in new diagnoses of this understudied condition.